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Research Article
Personalising laboratory medicine in the
‘real world’: Assessing clinical utility, by clinical indication,
of serum total B12 and Active-B12
VR (holotranscobalamin)
in the diagnosis of vitamin B12 deficiency
Michael J Murphy1 , Fiona Brandie2, Mildred Ebare3, Michelle Harrison4, Ellie Dow1,
William A Bartlett5 and David Craig6
Abstract
Background: Assessing the pre- and post-test probability of disease in the context of routine health care is challenging. We
wished to study how test performance parameters relating to clinical utility vary by clinical indication in a ‘real-world’ setting.
Methods: The diagnostic accuracy of serum total B12 and Active-B12
VR (holotranscobalamin) was evaluated in a primary
care population, using serum methylmalonic acid as the reference standard. We used electronic requesting to establish
the clinical indication for each request. Routine requests from primary care for serum total B12 were included if
creatinine was also measured and estimated glomerular filtration rate was at least 60mL/min/1.73 m2.
Results: Clinical indications included peripheral neuropathy (n¼ 168), anaemia (n¼ 168), cognitive decline (n¼ 125),
suspected dietary deficiency (n¼ 76), other (n¼ 362). For peripheral neuropathy, the area under the receiver operator
curve� 95% confidence interval (AUC�CI) was 0.63 (0.54–0.71) (P¼ 0.002) for total B12 and 0.68 (0.60–0.77)
(P< 0.0001) for Active-B12
VR . For anaemia, AUC�CI was 0.56 (0.47–0.66) (P¼ 0.10) for total B12 and 0.69 (0.59–
0.78) (P< 0.0001) for Active-B12
VR . For cognitive decline, AUC�CI was 0.54 (0.43–0.65) (P¼ 0.26) for total B12 and
0.69 (0.58–0.80) (P¼ 0.0002) for Active-B12VR . The pre–post-test change in probability of disease varied by clinical
indication.
Conclusion: Combining diagnostic accuracy studies and electronic testing in a ‘real-world’ setting allows clinical utility
to be assessed by clinical indication. Wider application of this would permit more personalised laboratory medicine. In
this study, diagnostic performance of total B12 and Active-B12
VR varied across all indications. Active-B12
VR provided better
discrimination, but this may have reflected the cut-offs used.
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Introduction
Diagnostic investigations are most useful at the point
of maximum diagnostic uncertainty, i.e. when the
potential gap between pre- and post-test probability
of disease is greatest. In the context of routine health
care, it is difficult to study the application of this prin-
ciple to laboratory investigations. Practical challenges
include: first, the existence of multiple requests and
request sources, each with a potentially different pretest
probability of disease; second, the need for information
about the clinical indication for the request; third, the
need for a validated reference standard. As a result of
these difficulties, ‘real-world’ studies of the clinical util-
ity of tests, and how this varies by clinical indication,
are rare.
Separately, accurate assessment of vitamin B12
status is problematic.1 Defining deficiency in terms of
tissue stores (e.g. red cell cobalamin)2 is not always
feasible, and no single analytical measurement is
ideal, leading some to propose the use of combined
indicators of vitamin B12 status.
3 Several diagnostic
reports4–8 have used methylmalonic acid (MMA) as
reference standard, despite its acknowledged limita-
tions.9 We adopted this approach in a study of the
diagnostic accuracy of serum total B12 and Active-
B12
VR (holotranscobalamin, or holoTC) in the assess-
ment of vitamin B12 status in an otherwise unselected
primary care population. We used electronic requesting
to establish the clinical indication for each request. Our
study is the first to report how test performance param-
eters relating to clinical utility vary by clinical indica-
tion in a ‘real-world’ setting.
Methods
General practitioners in 68 practices in Tayside,
Scotland (population approximately 400,000) were
advised of the intention to perform a study of the diag-
nostic accuracy of the existing measure of vitamin B12
status (i.e. total serum B12), and Active-B12
VR (see below
for details of methods), in the setting of routine health
care. Their cooperation was sought in the provision of
information about the clinical indication for individual
requests. Clinical information was delivered through
an electronic order communications system, the
Integrated Clinical Environment (ICE) (Sunquest
Information Systems, Uxbridge, UK). The study was
performed between 12 June 2014 and 31 July 2014.
Participants
The study population consisted of consecutive patients
from whom samples were received for routine measure-
ment of total serum vitamin B12. In order to minimise
the impact of reduced glomerular filtration rate (GFR)
on serum MMA,10 patients were excluded if creatinine
was not concurrently requested or if estimated glomer-
ular filtration rate (eGFR) was 60mL/min/1.73 m2 or
less. Only the results of total serum vitamin B12
were reported.
Clinical indications
Health-care professionals ordering vitamin B12 through
the electronic order communications system chose
from the following ‘drop-down’ list of clinical indica-
tions: unexplained anaemia; macrocytic anaemia; cog-
nitive decline; suspected dietary deficiency; peripheral
neuropathy; other.
Analytical methods
Serum total B12 was measured by chemiluminescent
microparticle-based competitive immunoassay on an
Advia Centaur (Siemens Healthineers, Tarrytown,
NY, USA), Active-B12
VR by chemiluminescent
microparticle-based immunoassay on an Abbott
Architect i2000 (Abbott Diagnostics, Abbott Park,
IL, USA), both at Ninewells Hospital in Dundee.
MMA was measured using a MultiPurpose Sampler
(Gerstel GmbH, Mülheim an der Ruhr, Germany) cou-
pled to liquid chromatography tandem mass spectrom-
etry (MPS-LC-MS/MS) at the Nutristasis Unit,
Viapath, St Thomas Hospital, London.
Cut-offs used to define result categories
The lower limit of the reference interval (200 pg/mL)
for serum total B12 was used, in line with the manufac-
turer’s recommendations. The cut-off for serum
holoTC (Active-B12
VR ) was <35 pmol/L, as used by
other groups.6,11 Two separate cut-offs were used for
MMA, reflecting the impact of age-related changes in
glomerular function on serum MMA: >0.28 mmol/L
for patients 465 years and >0.36 mmol/L for patients
>65 years. These were defined using age-specific 97.5th
percentiles in vitamin B12-replete patients in a previous
study.12 Total B12, Active-B12
VR and MMA were mea-
sured in isolation from each other; respective assessors
of each did not have access to results of the other
measurements, and only laboratory staff involved in
the routine measurement of total B12 had access to
the clinical indication for each request.
Statistical methods
Descriptive statistics (mean, 2.5th and 97.5th centiles)
were calculated for population characteristics.
Test performance parameters and receiver operator
curve (ROC) analysis were performed by Analyze-it
(Version 2.21; Analyze-it Software Ltd, West
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Yorkshire, UK). Youden cut-offs were established for
the three commonest indications and test performance




During the study period, 899 routine requests for
serum total B12 were received. The breakdown of clin-
ical indications for requests was as follows: unex-
plained anaemia (n¼ 134), macrocytic anaemia
(n¼ 34), cognitive decline (n¼ 125), suspected dietary
deficiency (n¼ 76), peripheral neuropathy (168), other
(n¼ 362). (The anaemia categories were merged for the
purposes of data analysis.) Table 1 summarises group
characteristics for the three commonest indications.
For the other indications, the characteristics (mean
and 2.5–97.5 centiles) were as follows: (1) suspected
dietary B12 deficiency: age (years) 57 (15–91), haemo-
globin (g/L) 137 (109–165), haematocrit 0.42 (0.35–
0.50), mean cell volume (fL) 95 (85–110), white cell
count (�109/L) 6.4 (3.5–10.9), platelets (�109/L) 254
(108–406), total vitamin B12 (pg/mL) 370 (164–1004),
Active-B12
VR (pmol/L) 65 (12–256), MMA (mmol/L) 342
(96–1869); (2) other: age (years) 61 (23–92), haemoglo-
bin (g/L) 134 (99–165), haematocrit 0.41 (0.30–0.49),
mean cell volume (fL) 94 (81–111), white cell count
(�109/L) 6.8 (3.7–11.9), platelets (�109/L) 256 (130–
441), total vitamin B12 (pg/mL) 388 (170–974),
Active-B12
VR (pmol/L) 70 (17–256), MMA (mmol/L)
320 (95–1121).
ROC curves for the three commonest specific indi-
cations are shown in Figure 1(a) to (c). For other indi-
cations, the areas under the curve� 95% confidence
intervals (AUC�CI) were as follows for total B12: sus-
pected dietary deficiency 0.50 (0.36–0.64); other 0.47
(0.41–0.54). For Active-B12
VR , the AUC�CI were: sus-
pected dietary deficiency 0.61 (0.47–0.75); other 0.66
(0.60–0.72). For the total population, the AUC�CI
for total B12 was 0.53 (0.49–0.57) (P ¼ 0.075), and
for Active-B12
VR , AUC�CI was 0.68 (0.64–0.72) (P
< 0.0001). These AUC were significantly different
from each other (P < 0.0001).
Table 2 summarises the pre- and post-test probabil-
ities of vitamin B12 deficiency (as defined by raised
serum MMA), before and after measurement of
serum total B12, in each of the three commonest specific
indications for requesting total B12. Data are presented
using the preassigned cut-offs and using Youden cut-
offs (designed to optimise differentiating ability).13 We
wished to calculate the post-test probability of disease
in the presence of positive and negative results, respec-
tively; therefore, we replaced the negative predictive
values (NPV) by [1–NPV]. Table 3 summarises the cor-
responding data for Active-B12
VR .
Discussion
Optimal targeting of diagnostic tests in the setting of
normal care is challenging. Evaluations of diagnostic
accuracy are usually performed in well-defined and pre-
selected populations, whereas tests in routine use
are usually applied to multiple populations that
vary in terms of relevant parameters (e.g. prevalence).
In the current study, we have addressed this issue
by performing a diagnostic evaluation in the setting
of normal care.
We identified several distinct populations, based on
the clinical indication for the vitamin B12 request.
Patients with cognitive decline were, as anticipated,
older than other patient groups, and had higher creat-
inine, reflecting reduced glomerular function.
Interestingly, prevalence of vitamin B12 deficiency, as
defined by raised serum MMA, was broadly similar in
the patient groups defined by the three commonest
specific indications, ranging from 32.7% in patients
with peripheral neuropathy to 36.6% in patients with
anaemia. This is important, since any differences in
PPV and [1–NPV] across clinical indications are there-
fore not attributable to large differences in prevalence.
For all categories of indication, measurement of
Active-B12
VR reliably differentiated vitamin B12 deficien-
cy from non-deficiency, and for all the AUC for
Active-B12
VR was greater than for total B12, although
in the case of peripheral neuropathy, the difference
was not statistically significant. However, these find-
ings must be interpreted with caution in the context
of the wider literature. The effect on the clinical utility
of holoTC of applying different MMA cut-offs,8 and
more widely, the need to base cut-offs (for all vitamin
B12 biomarkers) on adverse outcomes,
14 have previous-
ly been highlighted. The age-specific MMA cut-offs
applied here, particularly in patients >65 years, may
have affected sensitivity and specificity; other limita-
tions include those of using MMA as a reference stan-
dard,15 and the exclusion of patients where creatinine
was not requested, or where eGFR was 60mL/min/
1.73 m2 or less. On the wider issue, the ability of
holoTC to predict, for example, neurological outcomes
like cognitive decline in well-designed studies16–19 has
been variable, and its role as a biomarker of clinically
meaningful vitamin B12 deficiency remains inconclu-
sive. Recent assessments15,20 acknowledge the limita-
tions of holoTC and other markers and endorse the
adoption of algorithm-based approaches that combine
more than one measure of vitamin B12 status.
3 This
seems reasonable, and our findings do not provide a
basis for challenging this position.
With these caveats, low Active-B12
VR results were
more useful than normal ones; the increase in proba-
bility of vitamin B12 deficiency seen with a low result
l. 3
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Age (years) 64 23–92
Haemoglobin (g/L) 133 96–165 27% (<120 female, <130 male)
Haematocrit 0.41 0.30–0.50 19% (<0.37)
Mean Cell Volume (fL) 94 81–110 8% (>105)
White Cell Count (109/L) 6.8 3.5–11.9 6% (<4 109)
Platelets (109/L) 257 126–447 7% (<150 109)
Total B12 (pg/mL) 408 171–1195 5% (<200)
Active-B12
VR (pmol/L) 67 15–256 24% (<35)






Age (y) 77 44–93
Haemoglobin (g/L) 132 94–166 30% (<120 female, <130 male)
Haematocrit 0.41 0.29–0.51 21% (<0.37)
Mean cell volume (fL) 95 83–107 6% (>105)
White cell count (109/L) 6.6 3.4–10.3 6% (<4 109)
Platelets (109/L) 263 135–479 7% (<150 109)
Total B12 (pg/mL) 413 166–1269 7% (<200)yo
Active-B12
VR (pmol/L) 62 16–256 34% (<35)yo







Age (y) 58 23–89
Haemoglobin (g/L) 142 110–168 7% (<120 female, <130 male)
Haematocrit 0.43 0.35–0.50 5% (<0.37)
Mean cell volume (fL) 94 84–106 2% (>105)
White cell count (109/L) 7.2 3.8–13.0 4% (<4 109)
Platelets (109/L) 258 126–434 4% (<150 109)
Total B12 (pg/mL) 410 205–838 1% (<200)
Active-B12
VR (pmol/L) 66 12–256 27% (<35)
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Age (years) 69 26–91
Haemoglobin (g/L) 121 87–159 62% (<120 female,
<130 male)
Haematocrit 0.38 0.28–0.50 43% (<0.37)
Mean cell volume (fL) 95 79–116 12% (>105)
White cell count (109/L) 6.8 3.0–11.9 10% (<4 109)
Platelets (109/L) 258 110–448 11% (<150 109)
Total B12 (pg/mL) 391 144–1541 8% (<200)
Active-B12
VR (pmol/L) 67 15–256 21% (<35)
MMA (mmol/L) 347 84–1149 34% (>0.284 65yo;
>0.36> 65yo)
Note: the upper measuring limit of the Active-B12
VR assay is 256 pmol/L; all samples 5256 pmol/L were recorded for analysis as 256 pmol/L. This does
not affect % abnormal results nor the clinical performance calculations. ‘Unexplained anaemia’ and ‘macrocytic anaemia’ categories were merged. In the




Figure 1. (a) ROC curves for total B12 and Active-B12
VR in the diagnosis of vitamin B12 deficiency (as defined by raised serum MMA) in
anaemia. (b) ROC curves for total B12 and Active-B12
VR in the diagnosis of vitamin B12 deficiency (as defined by raised serum MMA) in
cognitive decline. (c) ROC curves for total B12 and Active-B12
VR in the diagnosis of vitamin B12 deficiency (as defined by raised serum
MMA) in peripheral neuropathy.
l. 5
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was higher, for all three of the commonest specific
indications, than the decrease in probability associated
with a normal result (see Table 3). This was true
both when the preassigned cut-offs and when Youden
cut-offs were used. As anticipated, the PPV ranking for
these indications corresponded to the prevalence rank-
ing (when the preassigned cut-off was used), with the
highest PPV associated with anaemia and the lowest
with peripheral neuropathy.
We have shown in the current study that it is possi-
ble to apply the principles of evidence-based medicine
to routine requesting. Electronic requesting is now
commonplace in health care, and, with the co-
operation of clinical colleagues, can readily be
harnessed to studies of diagnostic accuracy. In the pres-
ence of a validated reference standard, it is possible to
establish prevalence by clinical indication and request-
ing source. The cost of diagnostic studies involving val-
idated reference standards should be offset against the
potential savings enabled by greater precision in labo-
ratory requesting, for example through the application
of local algorithms.
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was higher, for all three of the commonest specific
indications, than the decrease in probability associated
with a normal result (see Table 3). This was true
both when the preassigned cut-offs and when Youden
cut-offs were used. As anticipated, the PPV ranking for
these indications corresponded to the prevalence rank-
ing (when the preassigned cut-off was used), with the
highest PPV associated with anaemia and the lowest
with peripheral neuropathy.
We have shown in the current study that it is possi-
ble to apply the principles of evidence-based medicine
to routine requesting. Electronic requesting is now
commonplace in health care, and, with the co-
operation of clinical colleagues, can readily be
harnessed to studies of diagnostic accuracy. In the pres-
ence of a validated reference standard, it is possible to
establish prevalence by clinical indication and request-
ing source. The cost of diagnostic studies involving val-
idated reference standards should be offset against the
potential savings enabled by greater precision in labo-
ratory requesting, for example through the application
of local algorithms.
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